Dr. Alexandra M Vera
Urology
Early Adopter
Memorial Sloan Kettering
Dr. Alexandra M Vera is a Urology specialist at Memorial Sloan Kettering, NYC. Medicare panel of ~404 beneficiaries. Therapeutic focus spans Endocrine/Metabolic, Nephrology/Urology, and Oncology — with documented disease-state coverage across hypogonadism, prostate cancer, and erectile dysfunction.
Therapeutic Areas
- Endocrine/Metabolic
- Nephrology/Urology
- Oncology
Top Disease States
- Hypogonadism
- Prostate Cancer
- Penile Cancer
- Chronic Pain
- Diabetes Mellitus
Procedures/Injectables
| Year | CPT/HCPCS | Procedure Name | Volume | Patients | Medicare Allowed | Medicare Paid |
|---|---|---|---|---|---|---|
| 2023 | 99214 | Established patient office or other outpatient visit, 30-39 minutes | 149 | 141 | $12,248.28 | $9,798.62 |
| 2023 | 99204 | New patient office or other outpatient visit, 45-59 minutes | 104 | 104 | $10,279.14 | $8,223.31 |
| 2023 | 99213 | Established patient office or other outpatient visit, 20-29 minutes | 48 | 47 | $2,770.24 | $2,216.19 |
| 2023 | 93980 | Complete ultrasound of penis artery and vein blood flow | 32 | 32 | $1,595.61 | $1,276.49 |
Drugs
| Year | Drug | Generic | Scripts | Patients | Days of Supply | Total Drug Cost |
|---|---|---|---|---|---|---|
| 2023 | Testosterone | Testosterone | 30 | 12 | 1,670 | $6,959.72 |
| 2023 | Testosterone Cypionate | Testosterone Cypionate | 31 | 19 | 1,329 | $1,115.94 |
| 2023 | Clomid | Clomiphene Citrate | 12 | 0 | 624 | $921.43 |
Year-over-year payments
Top Companies
| Company | Total Amount | Top Products | Payment Type |
|---|---|---|---|
| Pfizer Inc. | $80,141.42 | VIAGRA, CAVERJECT | Consulting, Speaker, Travel |
| Auxilium Pharmaceuticals | $58,837.23 | XIAFLEX, STENDRA, TESTIM | Consulting, Speaker, Travel |
| Mylan Inc. | $20,719.10 | VIAGRA | Consulting, Travel |
| Endo Pharmaceuticals | $15,243.62 | XIAFLEX, AVEED, TESTOPEL | Consulting, Food and Beverage |
| Lilly USA, LLC | $15,474.97 | CIALIS | Consulting, Travel |
| AbbVie, Inc. | $12,990.02 | Androgel, Humira, Lupron | Consulting |
Active & Completed Trials
| Study | NCT ID | Phase | Role | Status | Sponsor |
|---|---|---|---|---|---|
| Enzalutamide + Leuprolide in Nonmetastatic Prostate Cancer (EMBARK) | NCT02319837 | Phase 3 | Investigator | Active | Astellas / Pfizer |
| Tadalafil After Radical Prostatectomy (REACTT) | NCT01026818 | Phase 4 | Publication Author | Completed | Eli Lilly and Company |
| Avanafil for ED Post-Prostatectomy | NCT00895011 | Phase 3 | Study Director | Completed | VIVUS LLC |
| Pharmacological Penile Rehabilitation After Bilateral Nerve-Sparing RP | NCT00955929 | NA | Principal Investigator | Terminated | Memorial Sloan Kettering |
| Prograf in the Prevention of ED After Radical Prostatectomy | NCT00106392 | Phase 4 | Publication Author | Completed | Astellas Pharma Inc |
PubMed Selected Publications
- Freedland SJ, Vera AM, Gleave M, et al. Effects of Enzalutamide on Sexual Activity in Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of EMBARK.
- Nascimento BCG, Vera AM, et al. Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy.
- Vera AM, Klein EA, Slawin K, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Tacrolimus for the Prevention of ED Following Bilateral Nerve-Sparing Radical Prostatectomy.
- Vera AM, Brock G, Oelke M, et al. Effects of Tadalafil Once-Daily vs Placebo on Return to Baseline Erectile Function After Radical Prostatectomy (REACTT).